Comparison of two different alpha1-adrenoceptor antagonists, tamsulosin hydrochloride and silodosin, in the treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A prospective randomized crossover study.
Comparison of two different alpha1-adrenoceptor antagonists, tamsulosin hydrochloride and silodosin, in the treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A prospective randomized crossover study.
复制标题
两种不同的α1-肾上腺素受体拮抗剂盐酸坦索罗辛和西洛多辛治疗提示良性前列腺增生的男性下尿路症状的比较：一项前瞻性随机交叉研究。
DOI：
10.1111/j.1757-5672.2011.00099.x
复制
发表时间：
2012
期刊：
影响因子：
1.3
通讯作者：
Nagai A
中科院分区：
文献类型：
--
作者：
Yokoyama T;Hara R;Fukumoto K;Fujii T;Jo Y;Miyaji Y;Nagai A
目的：评价两种α1受体拮抗剂坦索罗辛和西洛多辛治疗男性下尿路症状的疗效和安全性。46例患者被随机分为两组。治疗组23例，先用坦索罗辛0.2 mg，1次/d，疗程3个月，再用西洛多辛4 mg，每日2次，疗程3个月，对照组23例，先用西洛多辛，后用坦索罗辛(S组)。然后，患者在1个月的清理期后转向替代治疗。结果：共治疗男性46例，其中T组23例，S组23例，41例(89.1%)完成治疗。两组患者治疗后IPSS评分、生活质量指数、最大尿流率、排尿后残余尿量均有明显改善。治疗3个月时，S组和T组治疗后总IPSS的变化分别为−6.6和−7.5。两组间差异无统计学意义。在服用这两种药物后，18名患者倾向于西洛多辛，11名患者倾向于坦索罗辛，其他人认为他们有相同的效果。6例患者和0例患者分别在西洛多辛和坦索罗辛治疗期间发生不良事件。结论：同一个体中两种类型的α1-肾上腺素能受体拮抗剂具有相似的疗效。在选择治疗方法时，应考虑每种药物的概况和差异。
Objectives:We assessed the efficacy and safety of twoα1‐adrenoceptor antagonists, tamsulosin and silodosin, in the treatment of male lower urinary tract symptoms.Methods:Men aged 50 years or older who had a total International Prostate Symptom Score (IPSS) of 8 or higher were enrolled in this study. Forty‐six patients were randomized into two groups. Twenty‐three patients were initially prescribed tamsulosin 0.2 mg once daily for 3 months, followed by silodosin 4 mg twice daily for 3 months (group T); the other group of 23 patients were initially prescribed silodosin, followed by tamsulosin (group S). Patients then switched to the alternative treatment after a 1‐month clearance period. Evaluations included clinical determination of IPSS, quality‐of‐life index, maximum flow rate and postvoid residual urine volume before and after treatment.Results:A total of 46 men, 23 in group T and 23 in group S, were treated and 41 (89.1%) completed the treatment. IPSS, quality‐of‐life index, maximum flow rate and postvoid residual urine volume were significantly improved in both groups after treatment. The changes in the total IPSS from baseline in groups S and T at 3 months were −6.6 and −7.5, respectively. There were no significant differences between the two groups. After taking both medications, 18 patients preferred silodosin, 11 preferred tamsulosin and others felt they had the same effects. Six and none patients experienced adverse events during silodosin and tamsulosin treatment, respectively.Conclusion:Two types ofα1‐adrenoceptor antagonists in the same individuals provide similar efficacy. Profiles and difference of each drug should be considered in making treatment choice.